Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BioXcel Therapeutics (BTAI)

BioXcel Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BTAI
DateTimeSourceHeadlineSymbolCompany
25/06/202412:00GlobeNewswire Inc.BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or SchizophreniaNASDAQ:BTAIBioXcel Therapeutics Inc
19/06/202402:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
19/06/202402:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
19/06/202402:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
19/06/202402:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
17/06/202420:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
17/06/202419:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
17/06/202418:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
17/06/202418:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
12/06/202400:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
12/06/202400:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
04/06/202412:30Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:BTAIBioXcel Therapeutics Inc
28/05/202412:00GlobeNewswire Inc.BioXcel Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:BTAIBioXcel Therapeutics Inc
21/05/202412:00GlobeNewswire Inc.BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingNASDAQ:BTAIBioXcel Therapeutics Inc
09/05/202414:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BTAIBioXcel Therapeutics Inc
09/05/202412:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
09/05/202412:00GlobeNewswire Inc.BioXcel Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:BTAIBioXcel Therapeutics Inc
25/04/202412:00GlobeNewswire Inc.BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
24/04/202415:30GlobeNewswire Inc.BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingNASDAQ:BTAIBioXcel Therapeutics Inc
22/04/202412:00GlobeNewswire Inc.BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialNASDAQ:BTAIBioXcel Therapeutics Inc
10/04/202412:00GlobeNewswire Inc.BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s DementiaNASDAQ:BTAIBioXcel Therapeutics Inc
25/03/202411:00GlobeNewswire Inc.BioXcel Therapeutics Announces $25 Million Registered Direct OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
15/03/202411:00GlobeNewswire Inc.BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineNASDAQ:BTAIBioXcel Therapeutics Inc
12/03/202411:00GlobeNewswire Inc.BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:BTAIBioXcel Therapeutics Inc
01/03/202412:00GlobeNewswire Inc.BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
14/02/202412:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
13/02/202414:00GlobeNewswire Inc.BioXcel Therapeutics Announces Termination of Proposed Public OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
12/02/202417:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
12/02/202412:14GlobeNewswire Inc.BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)NASDAQ:BTAIBioXcel Therapeutics Inc
08/02/202422:27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BTAIBioXcel Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BTAI

Your Recent History

Delayed Upgrade Clock